Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncolytic virus therapy for cancer.
Goldufsky J, Sivendran S, Harcharik S, Pan M, Bernardo S, Stern RH, Friedlander P, Ruby CE, Saenger Y, Kaufman HL. Goldufsky J, et al. Among authors: friedlander p. Oncolytic Virother. 2013 Sep 23;2:31-46. doi: 10.2147/OV.S38901. eCollection 2013. Oncolytic Virother. 2013. PMID: 27512656 Free PMC article. Review.
Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.
Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM. Sivendran S, et al. J Invest Dermatol. 2014 Aug;134(8):2202-2211. doi: 10.1038/jid.2014.85. Epub 2014 Feb 12. J Invest Dermatol. 2014. PMID: 24522433 Free PMC article.
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
Kyi C, Roudko V, Sabado R, Saenger Y, Loging W, Mandeli J, Thin TH, Lehrer D, Donovan M, Posner M, Misiukiewicz K, Greenbaum B, Salazar A, Friedlander P, Bhardwaj N. Kyi C, et al. Among authors: friedlander p. Clin Cancer Res. 2018 Oct 15;24(20):4937-4948. doi: 10.1158/1078-0432.CCR-17-1866. Epub 2018 Jun 27. Clin Cancer Res. 2018. PMID: 29950349 Free PMC article.
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. Chesney J, et al. Among authors: friedlander p. J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 2017 Oct 5. J Clin Oncol. 2018. PMID: 28981385 Free PMC article. Clinical Trial.
Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Hodi FS, et al. Among authors: friedlander p. J Clin Oncol. 2008 Apr 20;26(12):2046-51. doi: 10.1200/JCO.2007.14.0707. J Clin Oncol. 2008. PMID: 18421059 No abstract available.
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Hodi FS, et al. Among authors: friedlander p. J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17. J Clin Oncol. 2013. PMID: 23775962 Free PMC article. Clinical Trial.
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D. Hodi FS, et al. Among authors: friedlander p. Cancer Immunol Res. 2014 Jul;2(7):632-42. doi: 10.1158/2326-6066.CIR-14-0053. Epub 2014 Apr 21. Cancer Immunol Res. 2014. PMID: 24838938 Free PMC article. Clinical Trial.
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.
Friedlander P, Wassmann K, Christenfeld AM, Fisher D, Kyi C, Kirkwood JM, Bhardwaj N, Oh WK. Friedlander P, et al. J Immunother Cancer. 2017 Aug 15;5(1):67. doi: 10.1186/s40425-017-0272-z. J Immunother Cancer. 2017. PMID: 28807052 Free PMC article. Clinical Trial.
175 results